Next Article in Journal / Special Issue
A Cassette Vector System for the Rapid Cloning and Production of Bispecific Tetravalent Antibodies
Previous Article in Journal
Welcome to Antibodies: A New Open Access, Multidisciplinary Journal
Antibodies 2012, 1(1), 2-18; doi:10.3390/antib1010002
Review

Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity

1,†
,
2,†,*  and 1
1 Department of Biology, University of Erlangen-Nuremberg, Erlangen 91058, Germany 2 Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH, Aachen 52074, Germany These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 28 February 2012 / Revised: 16 March 2012 / Accepted: 30 March 2012 / Published: 10 April 2012
(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)
View Full-Text   |   Download PDF [665 KB, uploaded 10 April 2012]   |  

Abstract

Here we review recombinant proteins with a capability for dual-targeting. These molecules address two different antigens on the same tumor cell and therefore are called “dual-targeting agents”. By virtue of binding a chosen pair of antigens on the malignant cell, preferential binding to antigen double-positive over single-positive cells can be achieved when both are present in the same environment. Therapeutic effects of such agents are based on different modes of action: (1) They can act as pro-apoptotic agents or by inhibiting pro-survival signals; (2) The dual recognition moiety can be fused to effector-domains, such as bacterial toxins or other drugs, leading to the generation of bispecific antibody-drug conjugates (ADCs); (3) Dual-targeting agents can further be used to redirect an effector-cell to the tumor. A new generation of scFv-derived fusion proteins are the tandem single chain triplebodies (sctbs), which carry two scFv binding sites for antigens on the tumor cell plus a third, specific for a trigger molecule on an effector cell. The ability of preferential or selective targeting of antigen double-positive over single-positive cells opens attractive new perspectives for the use of dual-targeting agents in cancer therapy, and possibly also for the treatment of certain inflammatory and autoimmune disorders.
Keywords: dual-targeting; cancer therapy; effector cell; triplebody; NK-cell; macrophage; drug conjugates dual-targeting; cancer therapy; effector cell; triplebody; NK-cell; macrophage; drug conjugates
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Schubert, I.; Stein, C.; Fey, G.H. Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity. Antibodies 2012, 1, 2-18.

View more citation formats

Related Articles

Article Metrics

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert